3[6]Camm AJ,Yap YG.What should we expect from the next generation of antiarrhlunic drugs? J Cardiovasc Electrophysiol,1999,10:307-317 被引量：1
4[7]Roy D,Talajic M Dorian P,et al Amiodarone to prevent recurrence of atrial fibrillation.New Engl J Med,2000,342:913-920 被引量：1
5[8]Working Group on Arrhythmias of the European Society of Cardiology.Atral fibrillation:current knowledge and recommendations for management.Eur Heart,J 1998,19:1294-1330 被引量：1
2Antman EM, Anbe DT, Armstrong PW,et al.ACC/AHA guidlines for the management of patients with ST-elevation myocardial infarction-executive summary[J]. Circulation,2004,110:588 被引量：1
4Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology[J]. Arch Intern Med,2000,160:1 741 被引量：1
5The American Heart Association in Collaboration with the International Liais on Committee on Resuscitation. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6: Advance cardiovascular life support. Section 5: Phamacology I: Agents for Arrhythmias[J]. Circulation, 2000, 102(Suppl 8): I 112 被引量：1
6Fuster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation[J]. Eur Heart J,2001,22:1 852 被引量：1
8Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation[J]. N Engl J Med, 2002,347:1 825 被引量：1
9Maisal WH;Kantz KM;Reimold SC.Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital[J],1997(04). 被引量：1
10Kowey PR;Vanderlugt J;Luderer JR.Safety and risk/benefit of ibutilide for acute Conversion of atrial fibrillation/flutter[J],1996(78). 被引量：1
10Gibbons RJ,Antman BM,Alpertis,et al. Acc/AHA/ESC,guidelinfs for the management of patients with atrients fibrillation[J]. European Heart journal, 2001,22 : 1852. 被引量：1
